title: Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
abstract: The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope. The mean left ventricular ejection fraction was 36 +/- 9%. Baseline programmed cardiac stimulation initiated sustained VT (26 patients) or VF (16). The induced arrhythmia was not suppressed by conventional antiarrhythmic drugs in any patient (3 +/- 2 trials/patient). The mean daily dosage of sotalol was 221 +/- 84 mg. The right ventricular effective refractory period increased from 247 +/- 25 to 273 +/- 26 ms with sotalol (p = 0.0001) and the corrected QT interval increased from 431 +/- 35 to 456 +/- 62 ms (p = 0.02). Arrhythmia suppression was defined as no sustained VT or VF in response to programmed cardiac stimulation using up to 3 extrastimuli. Induced VT or VF was suppressed by sotalol therapy in 10 (24%) patients (group 1). Group 1 patients had faster induced arrhythmias at the baseline study than patients whose induced ventricular arrhythmia was not suppressed (group 2). The mean left ventricular ejection fraction tended to be higher in group 1 patients (p = 0.07). Fourteen patients (including 9 group 1 patients) continued receiving sotalol after discharge. In 2 group 2 patients, sotalol was combined with a class IA antiarrhythmic drug. During a mean follow-up period of 7.9 +/- 4.9 months, 2 patients had recurrent VT and in 2 others sotalol was discontinued due to side effects.
authors.affiliation: Cardiac Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114.
authors.forename: D L
authors.initials: DL
authors.lastname: Kuchar
authors.forename: H
authors.initials: H
authors.lastname: Garan
authors.forename: F J
authors.initials: FJ
authors.lastname: Venditti
authors.forename: D
authors.initials: D
authors.lastname: Finkelstein
authors.forename: J N
authors.initials: JN
authors.lastname: Rottman
authors.forename: J
authors.initials: J
authors.lastname: McComb
authors.forename: B A
authors.initials: BA
authors.lastname: McGovern
authors.forename: J N
authors.initials: JN
authors.lastname: Ruskin
mesh_terms: D000368:Aged; D003327:Coronary Disease / Q000150:complications; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications* / Q000503:physiopathology; D012008:Recurrence; D013015:Sotalol / Q000009:adverse effects / Q000627:therapeutic use*; D013318:Stroke Volume; D013610:Tachycardia / Q000188:drug therapy* / Q000503:physiopathology; D014693:Ventricular Fibrillation / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D013015:Sotalol